We are live on ! Find out more
CPX

Canaan Partners XI Portfolio holdings

AUM $127M
1-Year Est. Return 217.49%
This Fund
S&P 500
This Quarter Est. Return
+54.16%
1 Year Est. Return
+217.49%
3 Year Est. Return
+1,311.52%
5 Year Est. Return
10 Year Est. Return
AUM
$137M
AUM Growth
+$33.9M
Cap. Flow
-$4.28M
Cap. Flow %
-3.13%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
Reduced
1
Closed

Top Buys

Rank Stock Value
1
BLNK icon
Blink Charging
BLNK
+$14.8K

Top Sells

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$4.29M

Sector Composition

Rank Sector Weight
1 Healthcare 65.08%
2 Technology 34.92%
3 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TYRA icon
1
Tyra Biosciences
TYRA
$1.91B
$88.7M 64.85%
3,374,329
-233,780
-6% -$4.29M
AEVA
2
Aeva Technologies
AEVA
$1.26B
$47.8M 34.92%
3,597,039
RLYB icon
3
Rallybio
RLYB
$84.6M
$309K 0.23%
56,250
BLNK icon
4
Blink Charging
BLNK
$78M
$6.84K 0.01%
+10,260
New +$14.8K

Similar funds

Canaan Partners XI's Q4 2025 Portfolio in Review

As of Q4 2025, Canaan Partners XI held 4 positions worth $137M, up 33% from $103M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Canaan Partners XI withdrew a net $4.28M in Q4 2025, reducing 1 holding. Its largest reduction was Tyra Biosciences, cutting an estimated $4.29M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 49% a quarter earlier, followed by Technology and Industrials.

Against the trend, Canaan Partners XI opened a new position in Blink Charging worth $6.84K.

  • Canaan Partners XI's largest Q4 2025 buy was Blink Charging: 10,260 shares worth $6.84K.
  • Canaan Partners XI's biggest Q4 2025 reduction was Tyra Biosciences, cutting an estimated $4.29M.
  • Canaan Partners XI's ten largest holdings make up 100% of its $137M portfolio in Q4 2025.
  • Canaan Partners XI opened 1 new position and closed 0 in Q4 2025.
  • Canaan Partners XI's portfolio value rose 33% quarter-over-quarter to $137M.

Based on Canaan Partners XI's 13F filing for Q4 2025, filed 13 Feb 2026.